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                                        Once prostate cancer becomes hormone refractory, cancer 
cells may rapidly gain the ability to invade and to metastasize 
to lymph nodes and distant organs. Approximately one-third 
of patients treated for hormone-refractory prostate cancer 
will relapse, and there is no curative treatment for metastatic 
disease. 
  The progression through hormone-dependent to hormone-
refractory and metastatic prostate cancer is poorly understood, 
but some proteins with critical roles in the process have 
been partially characterized. Dissemination of tumor cells 
requires expression of metastasis-promoting genes involved 
in basement membrane degradation  —  metalloproteinases 
(MMPs), urokinase-type plasminogen activator (uPA), adhesion 
molecules, cell surface receptors, and many other proteins 
(  1  ). MMPs are endopeptidases that regulate cell growth, 
migration, and extracellular matrix remodeling and are expressed 
in primary prostate can    cer cells, osteoblasts, and osteoclasts 
(  2  ). MMP1 and MMP2 are highly expressed in metastatic 
cells, suggesting that they may have causal roles in tumor 
metastasis (  3    –    5  ). 
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     Background     Cyclin A1 is a cell cycle regulator that has been implicated in the progression of prostate cancer. Its role 
in invasion and metastasis of this disease has not been characterized.   
     Methods     Immunohistochemistry and cDNA microarray analyses were used to assess protein and mRNA expression 
of cyclin A1 and proteins with roles in metastasis, including vascular endothelial growth factor (VEGF), 
metalloproteinase 2 (MMP2), and MMP9, in human prostate cancer. Transient transfection and infection with 
viral vectors expressing cyclin A1 and short hairpin RNA (shRNA) targeting cyclin A1 were used to study the 
effects of altered cyclin A1 expression in PC3 prostate cancer cells. The BrdU assay, annexin V staining, and 
invasion chambers were used to examine cyclin A1 effects on proliferation, apoptosis, and invasion, respec-
tively. The role of cyclin A1 and androgen receptor (AR) in transcription of VEGF and MMP2 was assessed by 
promoter mutation and chromatin immunoprecipitation. The effect of cyclin A1 expression on tumor growth 
and metastasis was analyzed in a mouse model of metastasis. All statistical tests were two-sided.   
     Results     Cyclin A1 protein and mRNA expression were statistically significantly higher in prostate cancers than in 
adjacent benign tissues. A statistically significant correlation between expression of cyclin A1 and of MMP2, 
MMP9, and VEGF was observed in prostate tumors from 482 patients (  P   values from Spearman rank corre-
lation tests < .001). PC3 cells that overexpressed cyclin A1 showed increased invasiveness, and inhibition of 
cyclin A1 expression via shRNA expression reduced invasiveness of these cells. Eight of 10 mice (80%) 
bearing PC3 cells overexpressing cyclin A1 had infiltration of tumor cells in lymph node, liver, and lung, but 
all 10 mice bearing tumors expressing control vector were free of liver and lung metastases and only one 
mouse from this group had lymph node metastasis (  P   values from Fisher exact tests   <   .001). Cyclin A1, in 
concert with AR, bound to and increased expression from the VEGF and MMP2 promoters.   
     Conclusions     Cyclin A1 contributes to prostate cancer invasion by modulating the expression of MMPs and VEGF and 
by interacting with AR.   
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  Tumor cells invade either the blood or lymphatic vessels to 
access the general circulation and establish themselves in other tis-
sues. Vascular endothelial growth factor (VEGF) and its receptors 
play an important role in vessel formation, and high levels of 
VEGF are frequently observed in prostate cancer (  6  ,  7  ). VEGF 
stimulation can enhance the motility of targeted tumor cells in 
cooperation with MMPs and urokinase plasminogen activator 
(uPA)-mediated pathways (  8  ). Androgen receptor (AR), a member 
of the superfamily of ligand-activated nuclear receptors, plays a 
central role in the pathogenesis of primary and metastatic prostate 
cancer (  9  ,  10  ). Somatic mutations in the gene encoding this recep-
tor and its ampliﬁ  cation contribute to progression and metastasis 
of prostate cancer (  11    –    13  ). 
  Cyclin A1, a cell cycle regulatory factor, has been demonstrated 
to be required for the G2/M phase transition in meiotic division of 
male germ cells by gene targeting (  14  ), and it contributes to the 
G1/S cell cycle progression in leukemic cell lines (  15  ). Its role in 
pathogenesis of leukemia has been demonstrated in a transgenic 
mouse model in which targeted overexpression of cyclin A1 in 
early myeloid cells initiated acute myeloid leukemia in mice (  16  ). 
This study suggested that cyclin A1 has a cell cycle  –  independent 
function in carcinogenesis. Elevated levels of cyclin A1 expression 
have been observed in various types of solid tumors, including tes-
ticular, ovarian, and breast tumors (  17    –    19  ). The homeo-protein 
Six1 is functionally linked to cyclin A1 in breast cancer cell lines, 
and interactions between Six1 and cyclin A1 are needed to promote 
tumorigenic activity in breast cancer cells (  20  ). Recently, we have 
shown that cyclin A1 are highly expressed in advanced prostate 
cancer and that its expression is associated with tumor histology 
and VEGF expression (  21  ). However, the precise role of cyclin A1 
in the pathogenesis of primary and metastatic prostate cancer is 
largely unknown. 
  In this study, we investigated whether cyclin A1 contributes to 
prostate cancer invasion and metastasis and explored the molecular 
mechanisms by which cyclin A1 contributes to tumor metastasis. 
    Methods 
    Tissue Specimens and Tissue Microarrays 
  Paraffin-embedded sections of prostate samples from 482 patients 
with prostate cancer were obtained as archival specimens from the 
Department of Pathology at the University Hospital in Malmö. 
Hematoxylin  –  eosin (H&E)  –  stained slides of prostate biopsies were 
examined by a national board  –  certified pathologist (L. Helczynski). 
Selected areas of prostate cancer and corresponding benign samples 
were applied in duplicate to tissue microarray constructs of 1.0 mm 
in diameter. The study was approved by the Ethics Committee, 
Lund University, and the Helsinki Declaration of Human Rights 
was strictly observed.   
    Immunohistochemistry and Quantification of 
Angiogenesis 
  Immunohistochemistry on tumor tissue arrays was performed as 
previously described (  21  ). The slides were incubated with the fol-
lowing primary antibodies: anti  –  cyclin A1, 1:50 (Pharmingen, San 
Diego, CA); anti-VEGF, 1:100 (Santa Cruz Biotechnology, Santa 
Cruz, CA); anti-MMP9, 1:100 (Chemicon, Temecula, CA); anti-
MMP2, 1:100 (Lab Vision, Fremont, CA); and anti-AR, 1:200 
(Dako, Glostrup, Denmark A/S). Anti-rabbit or anti-mouse 
peroxidase  –  conjugated secondary antibodies were applied. 
Diaminobenzidine colorimetric reagent solution from Dako was 
used. Slides were counterstained with hematoxylin (Sigma, St 
Louis, MO). The specimens were viewed with an Olympus BX51 
microscope at magnification of ×20 or ×40. The staining intensity 
was scored as 0 (negative), 1 (weakly positive or positive), 2 (moder-
ate positive), 3 (strongly positive), or 4 (very strong positive) using 
an arbitrary semiquantitative scale as previously described (  21  ). The 
scores are representative for at least 60%  –  70% of the area of tissue 
analyzed, and the highest score for both cytoplasmic and nuclear 
compartments was considered in the statistical analyses. For analy-
sis of tumor angiogenesis, tumor sections were stained with an 
antibody against CD31 (BD Pharmingen, San Diego, CA, and 
Dako). Regions of high vascular density within the tumors were 
examined. The number of CD31-positive pixels per microscopic 
field was recorded. At least two sections per tumor and three views 
per section were determined.   
    Cell Culture and Androgen R1881 Treatment 
  Human prostatic cell lines LNCaP and PC3 were purchased from 
the American Type Culture Collection (Manassas, VA), and 
treatment with the synthetic androgen R1881 (Dupont/NEN, 
Boston, MA) was performed as previously described (  22  ). Time-
resolved analyses of cyclin A1  –  GFP fusion protein in living 
cells in response to R1881 treatment were performed using 
a Fluorescence Zeiss Apoptome Axiovert microscope at ×40 
magnification.   
    CONTEXT AND CAVEATS 
    Prior knowledge 
  Cyclin A1 is a cell cycle regulatory factor that is highly expressed in 
human prostate cancers.   
    Study design 
  Cyclin A1 expression was altered in cultured prostate cancer cells 
by introducing expression vectors or RNA interference. The effect 
of alterations in cyclin A1 expression was examined in terms of 
cellular processes relevant to the progression of prostate cancer, 
including invasion of prostate cancer cells in vitro and in mouse 
models of tumor growth and metastasis, and regulation at the pro-
moter level of genes that play a role in metastasis.   
    Contribution 
  This work demonstrated, and characterized in some molecular 
detail, the role of cyclin A1 in promoting invasion and metastasis 
of prostate cancer cells.   
    Implications 
  A cell cycle regulatory factor may contribute to prostate cancer 
invasion and metastasis.   
    Limitations 
  The manipulations of cyclin A1 expression were confined to cell 
lines and animal models that may not recapitulate the process of 
prostate cancer invasion and metastasis in humans. 
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    Retroviral- and Adenoviral-Mediated Transduction 
  Micro-RNA  –  adapted short hairpin RNA (shRNAmir) against 
human cyclin A1 in pSM2 vector was obtained from Open 
Biosystems (Huntsville, AL). The shRNAmirCyclin A1   sequence 
was subcloned to MSCV-LTRmiR30-PIG (LMP) vector (Open 
Biosystems) with   Xho  I and   Eco  RI restriction enzymes. Clones were 
verified by restriction site analysis and sequencing. For production 
of retrovirus, HEK 293 packaging cells were transiently transfected 
with shRNAmir-  cyclinA1-1    -LMP, VSVG, and Gag-Pol plasmids 
by use of Lipofectamine 2000 (Invitrogen, Inc, Carlsbad, CA). 
Media containing viruses were collected every 12 hours, and super-
natants were added to the culture medium containing PC3 cells 
followed by further incubation for 14 hours. PC3 cells were then 
selected with 5   µ  g/mL of puromycin (Sigma) for 1 week, and the 
knockdown of cyclin A1 was tested by immunoblotting and reverse 
  transcription  –  polymerase chain reaction (RT-PCR). Adenoviruses 
containing cyclin A1 were prepared by standard protocols as previ-
ously described (  23  ). Adenovirus-cyclin A1 vector was also gener-
ated by cloning full-length cyclin A1 cDNA into the   Xba  I and   Sal  I 
sites of adenoviral vector pShuttle-PGK-EGFP vector kindlly pro-
vided by Dr. Xiaolong Fan (Department of Molecular Medicine 
and Gene Therapy, Lund University). This vector contains Ad5-
PGK1-IRES-EGFP-B-globin intron-poly A and pShuttle back-
bone. Cyclin A1 cDNA was cloned between PGK1 and IRES. This 
adenoviral vector carrying cyclin A1 cDNA was designated as Ad5-
Cyclin A1. The control vector was the empty adenoviral vector 
expressing EGFP and was designated as Ad5-Control. These vec-
tors were used for the induction of long-term expression of cyclin 
A1 in prostate cancer cell lines.    
    Mouse Models of Tumor Growth and Metastasis 
  Three sets of mouse experiments were performed. All animal 
experiments met the requirements of Lund University Animal Care 
Facility and the National Institutes of Health guidelines. To ana-
lyze of the effects of cyclin A1 overexpression in subcutaneous 
tumor xenografts, 40 athymic nude mice aged 8  –  12 weeks (Harlan 
Nederland  , Horst, The Netherlands) were used. For measurement 
of tumor growth, 10 of these mice were injected subcutaneously 
with PC3 cells infected with adenoviruses expressing cyclin A1  –
  EGFP and 10 mice were injected with PC3 cells infected with ade-
noviruses expressing control-EGFP (4 × 10  6   cells per mouse). 
Tumor diameters were measured twice weekly using calipers, and 
volumes were calculated using the equation   a  (  b    2  /2), where   a   and   b   
represent the larger and smaller diameters, respectively. Mice were 
killed 6 weeks after inoculation of tumor cells. Tumor invasion and 
metastasis was examined in the remaining 20 mice (10 injected with 
PC3 cells expressing cyclin A1  –  EGFP and 10 with PC3 cells 
expressing control-EGFP) that were killed 12  –  14 weeks after injec-
tion. For assessment of cyclin A1 knockdown in subcutaneous 
tumor xenografts, 20 mice were injected with PC3 cells infected 
with retroviruses containing cyclin A1 shRNA-EGFP or control 
shRNA-EGFP (4 × 10  6   per mouse, 10 mice per group). For assess-
ment of cyclin A1  –  overexpressing tumors in orthotopic tumor 
xenografts, eight mice were injected in their prostates with PC3 
cells (1 × 10  6   cells per mouse) infected with adenovirus expressing 
cyclin A1  –  EGFP or control-EGFP (four mice for each tumor 
type). Mice were killed by CO  2   asphyxia or by cervical dislocation. 
Prostates, lymph node, liver, lung, brain, spleen, and femurs were 
removed from each mouse. (These tissues have been taken from all 
the mice used in this study.) Half of the tissues were used for histol-
ogy and immunohistochemical analysis. For histology analysis, tis-
sues were fixed in 4% paraformaldehyde and embedded in paraffin. 
The sections were stained with H&E and were subjected to analysis 
under microscopy. The other half of the tissues were snap frozen in 
liquid nitrogen for use in protein analyses.   
    Immunohistochemistry 
  For immunohistochemistry of mouse organs, tissues were fixed for 
24 hours in 4% paraformaldehyde and embedded in paraffin. The 
following antibodies   were used: anti  –  cyclin A1, 1:50 (US Biological) 
and anti  –  cyclin A1, 1:100 (Santa Cruz Biotechnology); anti  –
  c  ytokeratin-5, 1:200 (CK5) and anti-CD31, 1:200 (BD Pharmingen 
and Dako); and anti-VEGF, 1:100 (Santa Cruz Biotechnology).    
    Detection of VEGF Expression by Enzyme-Linked 
Immunosorbent Assay 
  The enzyme-linked immunosorbent assay (ELISA) for the detec-
tion of human VEGF in tissue lysates was performed as previously 
described (  21  ). Briefly, tissue homogenate was diluted to the final 
concentration of 1 mg/mL and 100   µ  L of the lysate was used for 
measuring human VEGF using the VEGF ELISA kit (R&D 
Systems, Minneapolis, MN).   
    Cell Synchronization and Cell Cycle Analysis 
  To obtain cells in G0 cell cycle phase, LNCaP cells were starved in 
RPMI-1640 containing 0.1% fetal bovine serum for 48 hours as 
previously described (  24  ). Cells were then fed with medium con-
taining 10% FBS for 6 hours (G1 phase), followed by growth in 
medium containing 200   µ  M mimosine dissolved in ethanol (Sigma) 
for additional 24 hours (late G1 phase). To obtain G1/S cells, 2   µ  g/
mL aphidicolin in dimethyl sulfoxide (  Sigma) was added to the cells; 
after 24 hours, cells were washed and cultured in medium 
containing 10% FBS for additional 6 hours (S phase). Nocodazole 
(0.1   µ  g/mL) in DMSO (Sigma) was then added into the medium, 
and cells were grown for 30 hours (G2/M phase). Cells were har-
vested at different time points. A total of 1 × 10  6   cells were fixed and 
permeabilized. Cells were then washed twice with phosphate-
buffered saline   (PBS) containing 10% fetal calf serum and resus-
pended and incubated in PBS containing 5   µ  g/mL propidium iodide 
(Sigma), 100 mM sodium citrate, pH 7.3, and 0.05 mg RNase A 
(Sigma) for 20 minutes at 4°C. The cell fluorescence was measured in 
a FACSCalibur cytofluorometer (Becton Dickinson, Franklin Lakes, 
NJ) and analyzed using CELL Quest software (Becton Dickinson).   
    BrdU Proliferation Assay 
  The effect of cyclin A1 expression on cell proliferation was deter-
mined using the nonradioactive BrdU  –  based cell proliferation 
assay (Roche, Basel, Switzerland) according to the manufacturer  ’  s 
protocol. Twenty-four hours after transfection, PC3 cells (3 × 10  3   
cells per well) were incubated for 24 hours in a 96-well plastic plate 
that contained complete growth medium (triplicate cultures). BrdU 
was then added, and cells were cultured for another 8 hours. BrdU 
incorporation into the DNA was determined by measuring the 
absorbance at both 450 and 690 nm on an ELISA plate reader.   jnci.oxfordjournals.org    JNCI | Articles 1025
    Invasion Assay 
  The invasion of PC3 cells was measured using Boyden transwell 
chambers (Chemicon) according to the manufacturer’s protocol. 
Briefly, the cells were seeded onto the membrane of the upper 
chamber at a concentration of 3 × 10  4   in 400   µ  L medium. RPMI-
1640 medium containing 10% FBS was then added to the lower 
chamber. Cells that passed through the Matrigel-coated membrane 
to the lower chamber were stained with crystal violet and were then 
dissolved in 10% acetic acid. The absorbance of the stained cells 
was measured on an ELISA plate reader.   
    uPA Activity Assay and Zymography 
  uPA activities in conditioned medium of cells transfected with small 
interfering RNA (siRNA)   targeting uPA and control siRNA was 
measured with a colorimetric uPA activity assay kit (Millipore, 
Billerica, MA) following the manufacturer’s protocol. Zymography 
was performed using Novex Zymogram Gels (Invitrogen) following 
the manufacturer’s protocol. Briefly, PC3 cells were transfected with 
pCMS  -EGFP-Cyclin A1 or control pCMS-EGFP vector (see 
below), or cells were stably transduced with shRNA against cyclin 
A1; 24 hours after transfection or seeding the stably transduced cells, 
culture supernatants were collected, and equal amount of volumes 
were subjected to gelatin zymography experiment (Invitrogen).   
    Preparation of Nuclear and Cytoplasmic Extracts 
  Nuclear and cytoplasmic fractions from control LNCaP cells or 
LNCaP cells treated with R1881 were prepared using the subcellu-
lar fractionation kit from Pierce (Rockford, IL) following the man-
ufacturer’s protocol.   
    Plasmids, Transfection, siRNA, and Luciferase Assay 
  The pCMS-EGFP-Cyclin A1 and pCMS-EGFP plasmids have 
been described previously (  21  ). Human cyclin A1 cDNA (1.8 kb) was 
cloned into pCMS-EGFP plasmid at the   Xho  I and   Sal  I restriction 
sites. These vectors were used  in experiments assessing the effects 
of  induction of transient expression of cyclin A1 in prostate cancer 
cell lines. AR-pcDNA3.1 was kindly provided by Dr Steven Balk 
(Beth Israel Deaconess Medical Center, Harvard Medical School). 
pcDNA3.1 was purchased from Invitrogen. PSA-luc and control 
constructs were kindly provided by Dr Hans Lilja (Memorial Sloan-
Kettering Cancer Center, New York, NY). VEGF promoter con-
structs were kindly provided by Dr Dieter Marme (Tumor Biology 
Center, Freiburg, Germany) (  25  ). The fragment designated as 2068 
contains the full-length promoter; fragment 1340 consists of two 
activator protein-1 (Ap-1) sites; fragment 840 contains only one Ap-
1 site; and fragments 102, 105, 316, and 415 lack the Ap-1 motifs. 
Transient transfection of pCMS-EGFP-Cyclin A1, pCMS-EGFP, 
AR-pcDNA3.1, or luc vectors containing different fragments into 
prostate cancer cell lines was performed using the electroporation 
system with Nucleofection kit (AmaxaBiosystems, Gaithersburg, 
MD) according to the manufacturer’s instructions. In luciferase 
assay, 100  –  200 ng of luc plasmids were used. Luciferase activity was 
measured using the Luciferase Assay kit (Promega, Madison, WI) 
following the manufacturer’s protocol. siRNAs against MMP2, uPA, 
and VEGF and scrambled siRNA were purchased from Ambion  , 
Austin, TX. siRNA (50 nM) in 3.5   µ  L of nuclease-free water was 
transfected into 1 × 10  4   PC3 cells in a total volume 250   µ  L of 
Optimem medium using 7   µ  L of Lipofectamine 2000 (Invitrogen). 
Cells were used 24 hours later for invasion assays.   
    Immunoblotting and Immunoprecipitation Assays 
  Immunoblot analysis was performed as previously described (  21  ). 
Co-immunoprecipitation of cyclin A1 and AR was performed as 
previously described (  23  ). Protein extracts were separated on 12% 
sodium dodecyl sulfate (SDS)  –  polyacrylamide gels and were subse-
quently transferred to nitrocellulose membrane Hybond ECL 
(Amersham Pharmacia Biotech, Buckinghamshire, UK). The mem-
branes were probed with appropriate primary antibodies, including: 
anti  –  cyclin A1, 1:200 (Pharmingen and US Biological, Swampscott, 
MA) and anti  –  cyclin A1, 1:500 (Santa Cruz Biotechnology); anti  -
AR, 1:1000 (Dako); anti  –      -actin, 1:1000 and anti  –  lamin B, 1:1000 
(Santa Cruz Biotechnology); anti-uPA, 1:500 (American Diagnostics, 
Stamford, CT); and anti  –  prostate-specific antigen (PSA  ), 1:1000 
(code 2E9) (  26  ). Membranes were then incubated with horseradish 
peroxidase  –  conjugated secondary antibodies (Amersham Life 
Sciences, Alesbury, UK) at 1:5000 dilution and visualized using the 
Enhanced ChemiLuminescence detection   system (ECL) and ECL 
films (Amersham Pharmacia Biotech).   
    RNA Preparation, RT-PCR Analysis, and cDNA Microarray 
Analysis 
  RNA was isolated from PC3 cells as previously described (  21  ). 
cDNA was synthesized from 2   µ  g of RNA (Invitrogen) and was 
used for semiquantitative RT-PCR or real-time RT-PCR.     -Actin 
was used as an internal control. Primers for human VEGF were 
previously described (  27  ). The other primers were as follows: cyclin 
A1: 5  ′  -CTCCTCTCCCAGTCTGAAGA-3  ′   and 5  ′  -CAGGAAGT
TGACAGCCAGAT-3  ′  ; MMP2: 5  ′  -CGGCCGCAGTGACGGA
AA-3  ′   and 5  ′  -CATCCTGGGACAGACGGAAG-3  ′  ; MMP9: 5  ′  -
GACGCAGACATCGTCATCCAGTTT-3  ′   and 5  ′  -GCCGCGC
CATCTGCGTTT-3  ′  ; MMP11: 5 ′  -CGATGTGACGCCACTCA
CCTTT-3  ′   and 5  ′  -GGCCAGGGCTGGCCATATA-3  ′  ; MT1
MMP: 5  ′  -CCAGGGTCTCAAATGGCAACATAATGAAA-3  ′   
and 5  ′  -CCATGGAAGCCCTCGGCAAA-3  ′  ; GAPDH: 5  ′  -AACA
GCGACACCCACTCCTC-3  ′   and 5  ′  -GGAGGGGAGATTCAG
TGTGGT-3  ′  ; and     -actin: 5  ′  -CGCGAGAAGATGACCCAG
ATC-3  ′  , 5  ′  -TCACCGGAGTCCATCACGA-3  ′  . For cDNA 
microarray analysis, the experimental procedures have been 
described in Varambally et al. (  28  ). We used expression profiling data 
that were available in the Gene Expression Omnibus (GEO)   under 
accession number   GSE3325   (available at   http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE3325  ). We used the data from 
benign prostate tissues (n = 6, N1  –  N4, NX1, NX2, GEO Profiles 
numbers: GSM74875  –  GSM74880), clinically localized primary 
prostate cancer (n = 7, P1  –  P5, PX1-2-tissue pools, GEO Profiles 
numbers: GSM74881  –  GSM74887), and metastatic prostate cancer 
(n = 6, W1  –  W4, WX1-2-tissue pools, GEO Profiles numbers: 
GSM74888  –  GSM74893).   
    Chromatin Immunoprecipitation 
  LNCaP cells were incubated with 0.1 nM R1881 for 1 hour and 
then rinsed with PBS. Protein  –  DNA complexes were then cross-
linked with 5% formaldehyde in serum-free medium for 5 minutes. 
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the supernatant was collected. Immunoprecipitation was performed 
on 0.5  –  1 mg protein with antibody against cyclin A1 or IgG (nega-
tive control) by rocking samples with 40   µ  L G beads and 200   µ  g/mL 
salmon sperm DNA at 4°C in total volume of 500   µ  L for 3 hours. 
After incubation, beads were extensively washed with low-salt buf-
fer (RIPA) and DNA  –  cyclin A1 complexes were eluted with 200   µ  L 
elution buffer (1% SDS, 1× Tris-Acetate Buffer  ) by rocking the 
beads at room temperature for 15 minutes. To dissociate histone  –
  DNA complexes, 20   µ  L of 5 M NaCl was added and incubated for 
4 hours at 65°C. To release DNA fragments, proteinase K was 
added in incubation buffer (10-  µ  L 0.5 M EDTA, 20   µ  L 1 M Tris  –
  HCl, pH 6.5) and incubated for 1 hour at 45°C. DNA was purified 
by phenol  –  chloroform extraction. For PCR the following primers 
were used: human VEGF promoter: 5  ′  -CTGGCCTGCAGCAGA
CATCAAAGTGAG-3  ′   and 5 ′  -CTTCCCGTTCTCAGCTCCACA
AAC-3  ′   (amplicon:     913 to     783 bp in the promoter); and human 
MMP2 promoter: 5  ′  -TGTTCCCTAAAACATTCCCC-3  ′   and 
5  ′  - GTCTCTGAGGAATGTCTTCT-3  ′   (amplicon:     1340 to 
    1120 bp in the promoter).   
    Sequence-Based Structure Prediction 
  The secondary structure of cyclin A1 was predicted by using the 
SABLE server (  29  ).   
    Statistical Analysis 
  Possible pairwise correlations between the groups were analyzed 
using the Spearman rank correlation test. The statistical signifi-
cance of differences between groups was evaluated by paired 
Wilcoxon rank sum test and Student   t   test or Mann  –  Whitney tests 
(comparison of means), and the Fisher exact test was used for com-
parison of incidence, as indicated. For measurement of tumor 
growth, two-way repeated analysis of variance (ANOVA) was per-
formed using ANOVA test. All outcome variables are presented as 
the mean values with 95% confidence intervals (CIs). All data pre-
sented are representative of at least three independent experiments. 
All statistical tests were two-sided, and   P   values less than .05 were 
considered to be statistically significant.     
    Results 
    Expression of Cyclin A1, VEGF, and MMPs in Tumor 
Specimens From Prostate Cancer Patients 
  Because VEGF and MMPs play important roles in tumor metasta-
sis, we examined whether their expression was increased in pros-
tate cancer and whether their expression was correlated with that 
of cyclin A1 (  6  ,  7  ). Expression of cyclin A1, VEGF, MMP2, and 
MMP9 was examined by immunohistochemical analysis of tissue 
microarrays that contained primary malignant tumors and adjacent 
benign prostatic tissues from 482 patients with prostate cancers of 
various stages (  Figure 1   and   Supplementary Figure 1  , A, available 
online). Prostate cancer specimens had statistically significantly 
higher levels of cyclin A1, VEGF, MMP2, and MMP9 expression 
than adjacent benign specimens (all   P   < .001, Wilcoxon signed 
rank test;   Figure 1, A  , and   Supplementary Table 1  , available 
online). There were statistically significant correlations between 
cyclin A1 and VEGF expression (  r    2   = 0.656,   P   < .001, Spearman 
rank correlation test), cyclin A1 and MMP2 expression (  r    2   = 0.123, 
  P   < .001), and cyclin A1 and MMP9 ex  pression (  r    2   = 0.432,   P   < 
.001) (  Supple  mentary Table 2  , available online).         
  Using the gene expression proﬁ  les obtained from the cDNA 
microarray analyses reported by Varambally et al. (  28  ), we assessed 
the expression of genes encoding cyclin A1, VEGF, MMP2, and 
MMP9 in tumor specimens from benign prostatic hyperplasia 
(n = 6), primary prostate cancers (n = 7), and metastatic prostate 
cancers (n = 6). Expression of cyclin A1 and VEGF was statistically 
signiﬁ  cantly higher in metastatic prostate cancer specimens than in 
benign prostatic hyperplasia tissue and primary tumors (  Figure 1, 
B,   P     value from Mann  –  Whitney test for cyclin = .036,   P   value for 
VEGF <    .001). There was no statistically signiﬁ  cant difference in 
the levels of MMP9 in metastatic tumors compared with benign 
and primary tumors. In contrast to the immunohistochemistry 
result, MMP2 levels derived from cDNA microarrays were lower 
in metastatic tumors. The inconsistency between protein and 
mRNA may be due to the fact that a proportion of nontumor cells 
were present in samples used for the cDNA microarray assay 
because tissues containing metastatic tumor cells were grossly 
dissected.   
    Effect of Cyclin A1 Overexpression or Depletion on 
Invasion and Growth of PC3 Cells In Vitro 
  Based on the positive correlation between cyclin A1 expression 
and metastatic prostate cancer, we examined the role of cyclin A1 
in tumor cell invasion. We achieved temporary cyclin A1 overex-
pression by transiently transfecting PC3 cells with cyclin A1  –
  EGFP expressing vectors. Long-term overexpression of cyclin A1 
in PC3 cells was achieved by infecting PC3 cells with adenoviruses 
expressing cyclin A1  –  EGFP. The effect of cyclin A1 overexpres-
sion on the invasiveness of PC3 cells was assessed using Matrigel 
coated Boyden chamber invasion assays. A higher proportion of 
PC3 cells overexpressing cyclin A1 passed through a Matrigel-
coated membrane than of cells that did not overexpress cyclin A1 
  (    Figure 2  ). Mean absorbances of cells containing pCMS-
EGFP (designated as pCMS) and pCMS-EGFP-cyclin A1 
(pCMS-Cyclin A1) vectors were 0.098 and 0.170, respectively 
(difference = 0.072, 95% CI = 0.059 to 0.083;   P   < .001); mean 
absorbance of cells infected with Adeno-5-PGK-EGFP (Ad5-
Control) and Adeno-5-PGK-EGFP-Cyclin A1 (Ad5-Cyclin A1) 
were 0.118 and 0.218, respectively (difference = 0.100, 95% CI = 
0.064 to 0.136;   P   < .001). Thus, cells overexpressing cyclin A1 
were more invasive.         
  To determine if expression of cyclin A1 was required for 
invasion, we depleted endogenous cyclin A1 by infecting cells 
with retrovirus expressing cyclin A1 shRNA-EGFP. PC3 cells 
expressing cyclin A1 shRNA-EGFP displayed statistically signif-
icantly reduced invasiveness compared with control cells infected 
with shRNA-EGFP (  Figure 2, C  ; mean invasion for control 
shRNA = 0.236, mean absorbance of invaded cells containing 
cyclin A1 shRNA   = 0.166, difference = 0.070, 95% CI = 0.044 to 
0.096;   P   < .001). We further examined the effect of cyclin A1 
overexpression or depletion on proliferation and the cell cycle. 
There was no statistically signiﬁ  cant effect of overexpression or 
inhibition of cyclin A1 on the proliferation of PC3 cells as 
assessed by the nonradioactive BrdU assay (  Supplementary 
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      Figure 1    .       Evaluation of the expression of cyclin A1, vascular endothe-
lial growth factor (VEGF), metalloproteinase (MMP)9, and MMP2 in 
prostate cancer specimens.   A  ) Tissue microarrays of sections from 
benign tissue and adjacent tumor tissue designated as   Gleason grade 
3 (81%) or Gleason grade 4  –  5 (18%) were immunostained with anti-
bodies against cyclin A1, VEGF, MMP9, and MMP2. Differences in the 
expression of cyclin A1 (tumor n = 876, benign n = 856), VEGF (tumor 
n = 864, benign n = 787), MMP2 (tumor n = 806, benign n = 791), and 
MMP9 (tumor n = 863, benign n = 836) between groups were assessed 
using the paired Wilcoxon signed rank test (  P   < .001). The mean val-
ues of intensities of staining (  horizontal lines  ) with error bars repre-
senting 95% conﬁ   dence intervals for the mean are shown. The 
outliers are labeled by   open circles  . The   boxes   represent the distribu-
tion of the expression of each protein in the groups.   B  ) Dot plots 
showing the expression of genes encoding cyclin A1, VEGF, MMP9, 
and MMP2 in tumor specimens from patients with benign prostatic 
hyperplasia (BPH, n = 6), primary prostate cancers (n = 7), and meta-
static prostate cancers (Met, n = 6) analyzed by cDNA microarray. 
Differences between metastatic cancers (Met) and nonmetastatic dis-
ease (benign prostatic cancer and primary tumors in localized cancer) 
were assessed using the Mann  –  Whitney test.   P   values from two-sided 
tests are indicated.       
or depletion of cyclin A1 did not inﬂ   uence the progression 
through the cell cycle in PC3 cells (  Supplementary Figure 2  , C 
and D, available online).   
    Effect of Cyclin A1 Overexpression on Growth and 
Vascularization of Tumors In Vivo 
  We examined the effect of cyclin A1 expression on tumor growth and 
invasion in vivo using mouse tumor xenografts. Equal numbers of 
PC3 cells infected with adenoviruses containing cyclin A1  –  EGFP or 
control EGFP were subcutaneously injected into nude mice, and 
tumor volume was assessed for 42 days beginning 14 days postin-
jection. The growth of tumors expressing cyclin A1  –  EGFP was 
delayed compared with that of tumors expressing control-EGFP 
(  Figure 3, A  , mean volume on day 40 of control-EGFP = 1110 mm  3  , 
Cyclin A1  –  EGFP = 102 mm  3  , difference = 1010 mm 
3  , 95% CI = 434 
to 1580 mm  3 ;   P   = .005, two-sided   t   test; cyclin A1 overexpression 
effect:   P   = .003, sampling time effect:   P   = .014, cyclin A1 × sampling 
time effect:   P   = .03 [two-way repeated-  measures ANOVA test for 
tumor growth]).         
  We also characterized tumor histology and measured the 
expression of VEGF, uPA, CD31, and Ki-67, proteins that are 
important for invasion and metastasis. We observed statistically 
signiﬁ  cantly higher expression of VEGF, as measured by ELISA, 
in tumors expressing cyclin A1  –  EGFP compared with tumors 
expressing control-EGFP: mean VEGF expression in tumors 
formed by cells that were infected with control adenoviruses and 
adenoviruses expressing cyclin A1 was 2.03 ng/mL per mg protein 
and 2.64 ng/mL per mg protein, respectively (difference = 0.61 
ng/mL, 95% CI = 0.14 to 1.09 ng/mL;   P   = .016). These results 
were conﬁ   rmed immmunohistochemically   (    Figure 3, B    )  . We 
determined the extent of tumor vascularization by quantifying the 
expression of CD31 and formation of blood vessels in the tumor 
areas. There was a statistically signiﬁ  cant increase in CD31 expres-
sion in tumors overexpressing cyclin A1 (mean numbers of CD31-
expressing vessels in tumors formed from cells expressing 
control-EGFP and cyclin A1  –  EGFP were 4.2 and 46, respectively, 
difference = 42, 95% CI = 28 to 55;   P   < .001;   Figure 3, B  ). An 
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along with an increased level of uPA was also observed in tumors 
that overexpressed cyclin A1 (  Figure 3, C and D  ). Although 
growth of tumors overexpressing cyclin A1 was delayed, there was 
no statistically signiﬁ  cant difference in the fraction of cells express-
ing Ki-67, suggesting that cyclin A1 overexpression did not inhibit 
tumor cell proliferation (  Supplementary Figure 3  , A [available 
online]; mean positive Ki-67 cells among control and   cyclin A1  –
  overexpressing cells was 45 and 42, respectively, difference = 3, 
95% CI = 0 to 13;   P   = .45). Although cyclin A1  –  overexpressing 
tumors proliferated at similar rates compared with control tumors, 
the mean size of cyclin A1  –  overexpressing tumors was smaller.   
    Effect of Cyclin A1 shRNA on Tumor Invasion In Vivo 
  To further verify the effect of cyclin A1 on tumor invasion, we 
established tumor xenografts by subcutaneously injecting PC3 
cells expressing shRNA-EGFP (control shRNA) or cells express-
ing cyclin A1 shRNA-EGFP (cyclin A1 shRNA) into nude mice 
(10 mice per group). Tumor incidence and volume were assessed 
40 days later. Tumors appeared in all mice from the two groups. 
There was no statistically significantly difference in tumor size. 
We analyzed the histology of the H&E-stained sections of lymph 
nodes, livers, lungs, and bones from the two groups of mice and 
found that all the organs were free of metastasis. To examine the 
invasiveness of tumors with reduced cyclin A1 expression, we iso-
lated fresh tumor cells from the mice (four mice per group) and 
tested these cells in Matrigel-coated Boyden chamber invasion 
assays. Invasion of tumor cells expressing cyclin A1 shRNA-EGFP 
was statistically significantly less than that of tumor cells express-
ing control shRNA-EGFP (mean absorbances were 0.151 and 
0.180, respectively, difference = 0.029, 95% CI = 0.024 to 0.034; 
  P   < .001,   Supplementary Figure 3  , B, available online).   
    Effect of Cyclin A1 Overexpression on Tumor Metastasis 
  To investigate whether cyclin A1 overexpression promoted inva-
sion of PC3 tumor cells to secondary sites, we isolated lymph 
nodes, livers, lungs, and bones from the mice 12  –  14 weeks after 
subcutaneous implantation. In eight of 10 mice bearing PC3 cells 
overexpressing cyclin A1, there was infiltration of tumor cells into 
lymph node, liver, and lung. None of the 10 mice bearing PC3 
cells containing control vectors had liver and lung metastases. One 
control mouse had lymph node metastasis. The incidence of tumor 
metastasis to lymph nodes was 10% in control (Ad5-Control) mice 
and 80% in cyclin A1  –  overexpressing mice (Ad5  –  Cyclin A1) (  P   < 
.001, Fisher exact test). Cyclin A1 overexpression in livers, lymph 
nodes, and lungs was verified by immunostaining of all the tissues 
using antibody against cyclin A1   (    Figure 4, A  ). Because CK5 is 
expressed in PC3 prostate cancer cells but is absent in lymph node, 
lung, and liver in mouse tissues (  30  ), expression of CK5 was exam-
ined and quantified in livers, lungs, and lymph nodes from mice 
bearing cyclin A1  –  overexpressing tumors and control mice. The 
mean percentage of CK5-positive cells in livers of control mice 
and mice whose tumors overexpressed cyclin A1 was 0 and 21.6, 
respectively (difference = 21.6, 95% CI = 0.0 to 43.5;   P   = .05). In 
lungs the corresponding percentages were 0 and 37, respectively 
(difference = 37, 95% CI = 0.0 to 86;   P   = .12). The corresponding 
percentages in lymph nodes were 15.0 and 50.0, respectively (dif-
ference = 35.0, 95% CI = 0 to 109;   P   = .263) (  Figure 4, A  ). 
Histological examination of liver specimens showed that tumors 
cells overexpressing cyclin A1 infiltrated into the livers in 70% of 
the mice, but none of the control mice showed signs of liver infil-
tration by tumor cells (  Figure 4, B  ); the number of occluded vessels 
in the livers of control and cyclin A1  –  overexpressing mice was 0 
and 8.7 (difference = 8.7, 95% CI = 0 to 19;   P   = .09).         
  To further examine the effect of cyclin A1 overexpression on 
tumor metastasis, we established an orthotopic mouse model by 
inoculating PC3 cells that were infected with adenoviruses con-
taining cyclin A1-EGFP or control-EGFP into the prostates of 
nude mice (n = 4 mice per group). Metastasis was measured 30 days 
later. We observed liver and lung metastases in three of four mice 
bearing tumors overexpressing cyclin A1 when we examined 
H&E-stained sections prepared from livers and lungs of all the 
mice in the two groups. Only one mouse from the control group 
      Figure 2    .       Evaluation of the role of 
cyclin A1 in invasion of PC3 cancer 
cells in vitro. Invasiveness of PC3 
  cells transfected with pCMS-EGFP 
(pCMS) or pCMS-EGFP-A1 (pCMS  –
  cyclin A1) vectors (  A  ), with 
adenoviruses expressing   EGFP 
(Ad5-Control) or cyclin A1  –  EGFP 
(Ad5-Cyclin A1) (  B  ), or with retrovi-
ruses expressing cyclin A1 shRNA-
EGFP or control shRNA-EGFP (  C  ). 
Cells that passed through the 
Matrigel-coated membrane into the 
lower chamber stained with crystal 
violet and then dissolved in 10% 
acetic acid. The absorbance of 
the stained cells was measured on 
an enzyme-linked immunosorbent 
assay plate reader. Photo  micro-
graphs (top) were taken from the 
lower invasion chambers at ×4 mag-
niﬁ  cation. Data in graphs at bottom 
are means of three independent 
experiments, each performed in 
duplicate, with upper 95% conﬁ  -
dence intervals (**  P   < .001).       jnci.oxfordjournals.org    JNCI | Articles 1029
had metastases in the lung and liver. This result was also conﬁ  rmed 
by the assessment of CK5 staining in lungs and livers from the 
mice overexpressing cyclin A1 and control mice (four mice per 
group) (  Figure 4, C  , mean percentage of CK5-positive cells in 
lungs of controls and mice overexpressing cyclin A1 was 2.5 and 
20, respectively, difference = 18, 95% CI = 0.0 to 43;   P   = .13). All 
(16/16) lymph nodes analyzed from cyclin A1  –  overexpressing 
tumors had micrometastases compared with 45% (5/11) of lymph 
nodes in the control group, and this difference was statistically 
  signiﬁ  cant (  P   = .017). One of four cyclin A1  –  overexpressing 
mice had enlarged axillary, para-aortic lymph nodes, and spleen 
(  Supplementary Figure 4  , available online), as well as large colo-
nies of tumor cells positive for CK5 (  Figure 4, C  ), suggesting that 
metastatic growth was responsible for the enlargement. 
Furthermore, vascularization was determined by the quantiﬁ  cation 
of CD31-positive vessels in tumor areas. There were higher num-
bers of CD31-positive vessels in cyclin A1  –    overexpressing tumors 
than controls (mean CD31-positive vessels in control and cyclin 
A1  –  overexpressing mice was 7 and 18, respectively, difference = 
11, 95% CI = 1 to 22;   P   = .032).   
    Expression and Activity of MMP2 and MMP9 in Cyclin 
A1  –  Overexpressing Cells 
  MMP2 and VEGF mRNA expression levels were statistically 
significantly higher in PC3 cells transiently transfected with 
pCMS-EGFP-Cyclin A1 than in PC3 cells transfected with 
empty pCMS-EGFP vector, as measured by semiquantitative 
RT-PCR (  Supplementary Figure 5  , available online) and real-
time quantitative RT-PCR (  Figure 5, A  ). Gelatin zymography 
assays were performed to examine the effect of overexpression or 
inhibition of cyclin A1 on the activity of MMPs. PC3 cells 
expressing cyclin A1  –  EGFP displayed increased activity of 
MMP2 and MMP9 proteins, compared with control PC3 cells 
  (    Figure 5, B    )  . In contrast, the gelatinase activities of these pro-
teins were reduced in PC3 cells expressing cyclin A1 shRNA 
  (    Figure 5, B    )  . Because we observed strong effects of cyclin A1 
      Figure 3    .       The effect of cyclin A1 on the invasive 
phenotype of tumor xenografts in vivo. 
Subcutaneous xenografts were established with 
PC3 cells that contained adenovirus expressing 
cyclin A1  –  EGFP (cyclin A1 xenografts) or EGFP 
(control xenografts).   A  ) Growth of cyclin A1 and 
control xenografts (n = 10 mice per group). Mean 
tumor volumes and upper 95% conﬁ  dence inter-
vals are shown.   B  ) Immunohistochemical analysis 
of tumors overexpressing cyclin A1 and control 
tumors for the expression of vascular endothelial 
growth factor and CD31 on day 42.   C  ) Immunoblot 
showing the expression of cyclin A1 and uroki-
nase-type plasminogen activator (uPA) in control 
tumors and tumors overexpressing cyclin A1. 
Actin was probed with a speciﬁ   c antibody to 
control for differences in protein amounts as 
loading control.   D  ) Immunohistochemical analysis 
of uPA expression in control and cyclin A1 tumors. 
uPA expression is seen in human tumor PC3 
cells in cyclin A1  –  overexpressing tumor (Ad5  –
  Cyclin A1), and the uPA-positive tumor cells are 
located in the ﬁ  broblast capsule of the invasive 
front of the tumor area (as marked with the 
dashed line).       1030   Articles | JNCI  Vol. 100, Issue 14  |  July 16, 2008
overexpression on uPA and MMP2 levels in vivo, we attempted 
to determine which of them is involved in cyclin A1  –  mediated 
invasion. We used siRNAs corresponding to the mRNAs encod-
ing these proteins to inhibit the levels of uPA, MMP2, or VEGF 
in PC3 cells overexpressing cyclin A1 (  Supplementary Figure 5  , 
B and C, available online). We overexpressed cyclin A1 by tran-
siently transfecting PC3 cells with pCMS-EGFP-Cyclin A1 or 
empty pCMS-EGFP vectors. Reduced expression of MMP2 or 
uPA inhibited the cyclin A1  –  mediated invasion in vitro. Increased 
invasion of PC3 cells due to overexpression of cyclin A1 (mean 
absorbance of invaded control cells = 0.0823, mean absorbance 
value of invaded cyclin A1  –    overexpressing cells = 0.1033, difference 
= 0.021, 95% CI = 0.011 to 0.031;   P   = .004) was partially abro-
gated when uPA was depleted in the cells by introduction of cor-
responding siRNA (mean absorbance of invaded control cells 
expressing control siRNA = 0.1033, mean absorbance of invaded 
cells expressing siRNA targeting uPA = 0.072, difference = 0.031, 
95% CI = 0.018 to 0.044;   P   < .001) or when MMP2 was depleted 
(means absorbance of invaded control cells expressing control 
siRNA = 0.103 invaded cells expressing siRNA targeting MMP2 = 
0.083, difference = 0.021, 95% CI = 0.003 to 0.037;   P   = .024). 
However, inhibition of VEGF did not prevent the increase in 
invasion mediated by cyclin A1 overexpression (  P   = .46). These 
results suggest that uPA and MMP2 are important for cyclin 
A1  –  mediated invasion (  Figure 5, D  ). Thus, our findings suggest 
that cyclin A1 may promote tumor cell invasion in part through 
uPA- and MMP2-mediated pathways.           
    Interaction of Cyclin A1 With AP-1 Sites Within the 
Promoters of VEGF and MMP2 
  Next, we investigated whether cyclin A1 contributes to tumor cell 
invasion by regulating the expression and activity of genes encod-
ing VEGF and MMP2. We performed chromatin immunoprecipi-
tation (ChIP)  –  binding assays in androgen-dependent LNCaP 
cells. In LNCaP cells treated with R1881, a synthetic androgen, 
cyclin A1 precipitated with the VEGF promoter region (  Figure 6, 
A  ). To define the sites on the VEGF promoter to which cyclin A1 
binds, seven VEGF sequences spanning different transcription 
factor  –  binding sites in the promoter were constructed and cloned 
so that they controlled luciferase expression: fragment 2068 
      Figure 4    .       Effect of cyclin A1 on metastasis 
of prostate cancer cells in vivo.   A  ) Im  -
munohistochemical analysis of cyclin A1 
and cytokeratin-5 (CK5) in livers, lungs, and 
lymph nodes of mice bearing control and 
cyclin A1  –  overexpressing tumors. About 5  –
  10 sections were prepared from each tissue 
examined.   B  ) Histology of the metastasis in 
the liver in mice bearing tumors with over-
expression of cyclin A1 compared with 
noncancerous livers of mice whose tumors 
did not overexpress cyclin A1.   C  ) De  -
pendence of CK5 expression on cyclin A1 
activity in an orthotopic mouse model of 
metastasis. PC3 cells overexpressing cyclin 
A1, or control PC3 cells expressing vector 
were orthotopically injected into mouse 
prostates, and the resulting metastasis was 
assessed 30 days later for organ histology 
and for CK5 expression. Sections of lymph 
nodes, lungs, and livers stained with anti-
body against CK5 are shown. The   arrows   
indicate the portal vein areas in the liver 
sections. The   inﬁ  ltrated human PC3 tumor 
cells in the portal vein areas in the cyclin A1  –
  overexpressing liver are positively stained 
with CK5.       jnci.oxfordjournals.org    JNCI | Articles 1031
contained the full-length promoter; fragment 1340 contained two 
Ap-1 sites; fragment 840 contained only one Ap-1 site; and frag-
ments 102, 105, 318, 415 lacked Ap-1 motifs (  Figure 6, B  ). The 
constructs were cotransfected with cyclin A1  –  EGFP or control 
vectors into LNCaP cells for 24 hours followed by treatment with 
0.1 nM R1881 (  Figure 6, B    )  . Cyclin A1 overexpression did not 
induce luciferase activity from promoter sequences lacking Ap-1 
sites (102  –  415). In the presence of cyclin A1 expression we observed 
higher expression of luciferase under the control of promoter frag-
ment 840 with only one Ap-1 site (mean value of luciferase activi-
ties from the control promoter and the promoter containing one 
Ap-1 site [840] in the presence of cyclin A1 expression was 0.011 and 
0.074, respectively, difference = 0.063, 95% CI = 0 to 0.115;   P   = 
.078). Cyclin A1 greatly increased luciferase expression from a 
promoter sequence that contained two closely spaced putative Ap-
1 sites (1340) (  Figure 6, B  ) (mean value = 0.1093, difference = 
0.098, 95% CI = 0.0516 to 0.145;   P   = .026). The effect of cyclin A1 
on this region was even greater when cells were treated with 0.1 
nM R1881 for 24 hours (means value of luciferase expression from 
control and the promoter containing the putative sites in the pres-
ence of R1881 was 0.018 and 0.159, respectively, difference = 
0.141, 95% CI = 0.0852 to 0.197;   P   = .019). Analysis of the cyclin 
A1 amino acid sequence revealed that it contains a leucine zipper  –
  like motif with helix-loop-helix structure similar to that of the jun 
transcription factor (  Figure 6, C  ). To examine whether cyclin A1 
occupied the Ap-1 sites located in the promoter regions of MMPs, 
we performed additional ChIP assays. Similar to what was observed 
for VEGF, cyclin A1 was bound to the MMP2 promoter in 
LNCaP cells treated with R1881 and in PC3 cells (  Figure 6, D  ).           
    Interaction of Cyclin A1 With AR in Prostate Cancer Cells 
  Because cyclin A1 binds to the VEGF and MMP2 promoters in 
LNCaP cells in an androgen-dependent manner, we investigated 
how cyclin A1 associates with AR. We examined the expression of 
cyclin A1 and AR in the tissue microarrays containing 99 prostate 
cancers that were chosen from a total of 482 because they were 
scored with higher Gleason grades and were therefore defined 
as advanced prostate cancers. There was a statistically significant 
correlation between cyclin A1 and AR expression in the 99 speci-
mens from advanced cancers (  r    2   = 0.214,   P   = .036) (  Figure 7, A  , 
  Supplementary Table 3  , available online). We have previously 
shown that the regulation of VEGF promoter by cyclin A1 is par-
tially dependent on AR in prostate cancer cell lines (  21  ). Therefore, 
we determined if AR interacted physically with cyclin A1. A com-
plex between cyclin A1 and AR was detected in both control and 
R1881-treated LNCaP cells using antibodies to cyclin A1 to pre-
cipitate the complex and antibody to AR for detection on immu-
noblots or antibody to AR for immunoprecipitation and antibody 
to cyclin A1 for detection on immunoblots (  Figure 7, B  ).           
    The Effect of AR Stimulation on Cyclin A1 Localization in 
Prostate Cancer Cells 
  To determine whether localization of cyclin A1 was affected by 
androgen stimulation, we assessed expression of cyclin A1 and AR 
in cytosolic and nuclear fractions of LNCaP cells that had been 
treated or not treated with R1881. An increase in the levels of both 
proteins was observed in the nuclear fraction after treatment with 
0.1 nM R1881 over a period of 2  –  4 hours (  Figure 7, C and D  ). This 
time-dependent increase suggests that R1881 either promotes 
nuclear translocation or mediates cyclin A1 stabilization in the 
nucleus. To test whether androgen effects on the subcellular distri-
bution of cyclin A1 are mediated via AR, LNCaP cells were trans-
fected with the AR-pcDNA3.1 expression vector or a control 
   
  Figure 5    .       Activation of metalloproteinases (MMPs) in PC3 cells overex-
pressing cyclin A1.   A  ) Quantitative real-time polymerase chain reaction 
(Q-PCR) for vascular endothelial growth factor (VEGF), MMP2, and 
MMP9 was performed using RNA isolated from PC3 cells infected 
with adenoviruses expressing EGFP (C) or Cyclin A1  –  EGFP (A1). 
  B  ) Assessment of MMP2 and MMP9 activity using gelatin zymography. 
Culture media of PC3 cells transfected with pCMS-EGFP (C) or pCMS-
EGFP-Cyclin A1 (A1) or culture media of PC3 cells infected with cyclin A1 
shRNA or control shRNA (C) were subject to electrophoresis, and MMP9, 
MMP2, and small size MMP2   activities were distinguished based on 
electrophoretic mobility.   C  ) Invasiveness of PC3 cells overexpressing 
cyclin A1 and/or expressing siRNA constructs targeting urokinase-type 
plasminogen activator, MMP2, or VEGF. Data are means of three inde-
pendent experiments performed in duplicate with upper 95% conﬁ  dence 
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pcDNA3.1 vector and treated with R1881 for 2 or 4 hours. AR 
overexpression in combination with R1881 treatment resulted in an 
increase in the overall expression of cyclin A1 relative to levels in 
cells transfected with vector alone with a much more pronounced 
increase in nuclear cyclin A1 expression (  Figure 7, E and F  ), sug-
gesting that AR is involved in cyclin A1 translocation to the nucleus. 
In PC3 cells that lacked a functional endogenous AR and were 
treated with R1881, overexpression of AR induced a maximal 
increase in cyclin A1 expression only in the nucleus (  Supplementary 
Figure 6  , available online). To confirm our observation that andro-
gen-triggered activation of AR is involved in cyclin A1 transloca-
tion to the nucleus, we performed time-resolved studies on live cells 
in which a construct encoding cyclin A1  –  GFP fusion protein was 
transfected into LNCaP cells. LNCaP cells that had been tran-
siently transfected with vectors that expressed cyclin A1  –  GFP or 
GFP alone were treated with R1881, and fluorescence images were 
taken every 3 minutes for 30 minutes. Although the subcellular 
location of control GFP did not change after R1881 treatment, we 
observed rapid translocation of cyclin A1  –  GFP to the nucleus 
(  Supplementary Figures 7  , A  –  C, and 8, A and B, available online).   
      Figure 6    .       Evaluation of the role of cyclin A1 in mediating vascular 
endothelial growth factor (VEGF) transcriptional activity. 
  A  ) Chromatin immunoprecipitation (ChiP) in LNCaP cells or in LNCaP 
cells treated with 0.1 nM R1881, a synthetic androgen. Polymerase 
chain reaction (PCR) was performed on immunocomplexes obtained 
by precipitation with antibody to cyclin A1 or to IgG (Control); Lysate = 
total lysate.   B  ) The schematic organization of the VEGF promoter 
(  25  ). Consensus sites for Ap-1 (  ﬁ  lled black squares  ) and Ap-2 (  open 
circle  ) along with translation start site and Sp-1 sites are indicated. 
Luciferase assay was performed in LNCaP cells that were cotrans-
fected with pCMS-EGFP-A1 and various VEGF promoter fragments 
and treated with R1881 or vehicle for 24 hours. (The   P   values for 
each comparison to examine the effect of cyclin A1 overexpression 
on VEGF promoters  were: promoter fragment 102:   P   = .395; 105: 
  P   = .354; 318:   P   = .780; 415:   P   = .132; 840:   P   = .078; 1340:   P   = .026, 
full-length promoter:   P   = .016; two-sided   t   test.) (The   P   values for 
each comparison to examine the effect of cyclin A1 overexpression 
in combination with R1881 were: promoter fragments 102:   P   = .495; 
105:   P   = .028; 318:   P   = .005; 415:   P   = .076; 840:   P   = .01; 1340:   P   = .019; 
full-length promoter:   P   = .016; two-sided   t   test.)   C  ) Secondary struc-
ture of cyclin A1 that forms the leucine-like zipper fragment. The 
helix-coiled-helix loop is underlined (H = helix; C = coil).   D  ) ChiP assay 
in LNCaP cells or in LNCaP cells treated with 0.1 nM R1881 (+) and in 
PC3 cells. PCR was performed with cyclin A1 immunocomplexes as 
template; primers spanning the Ap-1 site as described in “Materials 
and Methods” in the metalloproteinase 2 promoter were used to 
amplify precipitated sequences.       jnci.oxfordjournals.org    JNCI | Articles 1033
    Cyclin A1 Transactivation of AR on the PSA Promoter 
  Finally, we asked whether a change in the levels of cyclin A1 is 
associated with changes in AR-mediated gene expression. PSA 
promoter activity was determined in LNCaP cells overexpressing 
cyclin A1, AR, or both proteins followed by treatment with R1881. 
Although cyclin A1 by itself did not increase the activation of the 
PSA promoter to a statistically significant extent when cyclin A1 
was cotransfected with AR into the LNCaP cells, the activity of 
the PSA promoter and PSA protein levels were greatly increased 
compared with cells transfected with AR alone (  Figure 8, A and B  ). 
Similar to what was observed in LNCaP cells, the greatest increase 
in PSA expression was observed upon coexpression of cyclin A1 
and AR in PC3 cells lacking a functional AR, followed by the treat-
ment with 0.1 nM R1881 (  Supplementary Figure 8  , C, available 
      Figure 7    .        Evaluation of the associations between androgen receptor 
(AR) and cyclin A1 in patients and in LNCaP cells.  A  ) Immunohistochemical 
analysis of cyclin A1 and AR in prostate cancer tissue samples. Cyclin A1 
staining is shown in panels   a   and   b  ; AR staining is indicated in   c   and   d  . 
  B  ) Immunoprecipitation of cyclin 1 complexed to AR in LNCaP cells. 
Antibodies to AR and cyclin A1 were used for immunoprecipitation in 
the upper and lower panels, respectively, and for detection on immu-
noblots in the lower and upper panels, respectively. C = untreated con-
trol cells, R1881 = synthetic androgen  –  treated cells, IgG = negative 
control.   C   and   D  ) Nuclear and cytoplasmic fractions from LNCaP control 
cells and LNCaP cells treated with R1881 for the indicated times, elec-
trophoresed, transferred to nitrocellulose membranes, and probed with 
antibodies to cyclin A1 and AR.   E   and   F  ) Expression of cyclin A1 and AR 
was examined in the subcellular fractions from LNCaP cells transfected 
with control vector or AR vector in the presence or absence of R1881 
treatment (2  –  4 hours). Chemiluminescent reactions were allowed to 
proceed for the indicated times.       1034   Articles | JNCI  Vol. 100, Issue 14  |  July 16, 2008
online). These results suggest that cyclin A1 acts as a coactivator 
of AR.             
    Discussion 
  In this study we found that cyclin A1 plays an important role in pros-
tate cancer invasion and metastasis. We demonstrated that cyclin A1 
expression was elevated in most of the primary and metastatic prostate 
cancer specimens examined compared with adjacent benign speci-
mens. Furthermore, there was a statistically significant correlation 
between cyclin A1 and VEGF, MMP2, and MMP9 protein expres-
sion in tumor specimens from prostate cancer patients. Overexpression 
of cyclin A1 in PC3 cells by transient transfection or by adenoviral 
transduction promoted tumor cell invasion in vitro, and the cells 
became more invasive in vivo and metastatic. Silencing of cyclin A1 by 
shRNA inhibited migration and invasion in PC3 cells. We also dem-
onstrated that inhibition of MMP2 or uPA by siRNA-mediated 
knockdown could partially inhibit the increased invasiveness of PC3 
cells that overexpressed cyclin A1. Our data suggest that cyclin A1 
may promote tumor cell invasion in part by increasing the expression 
and activity of MMPs, uPA, and VEGF. In addition, we showed that 
induced AR expression enhanced nuclear cyclin A1 expression. 
Finally, we observed that cyclin A1 interacted with AR and enhanced 
AR-mediated activation of AR target genes, suggesting that cyclin A1 
and AR may act as cofactors, possibly to promote prostate tumor pro-
gression and invasion. 
  To mimic the gradual low-level dissemination of carcinoma 
cells in vivo, we used both subcutaneous and orthotopic xenograft 
models. We detected lymph node and lung metastases, regardless 
of primary tumor size, in mice bearing tumors overexpressing 
cyclin A1, but not in mice bearing tumors expressing control vec-
tors. Despite their more aggressive and metastatic properties, 
cyclin A1  –  transduced cells proliferated at similar rates in vitro and 
the mean size of tumors overexpressing cyclin A1 was smaller than 
that of tumors expressing control vectors. One possible interpreta-
tion for these results is that PC3 cells overexpressing cyclin A1 
may tend to spread rather than grow. Our ﬁ  ndings are supported 
by results of several other studies. For example, breast tumors with 
alterations in the HER-2 gene could invade into the lung without 
forming larger tumors in mouse models, and the number of dis-
seminated cancer cells was similar for small and large tumors in 
patients with HER-2 alterations (  31  ). Vascular endothelial growth 
factor-C   expression has also been shown to promote metastasis of 
lung tumors without promoting proliferation in tumor cells (  32  ). 
Similarly, overexpression of p16 not only increased invasiveness in 
tumors in breast and colorectal cancers but also inhibited cell cycle 
(  33  ). 
  The subcutaneous and orthotopic xenograft tumors overex-
pressing cyclin A1 also had higher levels of vascularization and 
angiogenesis than control tumors as reﬂ  ected by higher CD31 and 
VEGF expression. The fact that cyclin A1  –  overexpressing tumors 
did not grow larger than control tumors agrees with recent ﬁ  nd-
ings that higher vascularization does not always correlate with 
tumor growth (  34  ). 
  We demonstrated that cyclin A1 regulates VEGF and MMP2 
expression by binding directly to their promoters. Overexpression 
of cyclin A1 also enhanced the activities of MMPs. When we intro-
duced cyclin A1  –  expressing vector into PC3 cells together with 
constructs expressing siRNAs to MMP or uPA, we found that 
reduced expression of MMPs and uPA inhibited the cyclin A1  –
  mediated invasion and migration in vitro. The ﬁ  nding that cyclin 
A1 regulates the expression of a growth factor signaling molecule 
(VEGF) and extracellular proteases (MMPs) and promotes tumor 
cell invasion and metastasis in part through MMPs and uPA sug-
gests that cyclin A1 may be a key regulator of tumor invasion and 
metastasis. 
  The mechanisms underlying the transition from androgen 
dependent to androgen-independent metastatic cancer are 
unknown, but an important ﬁ   nding is the strong increase in 
expression of AR that is associated with the transition to latter 
condition (  11  ). R1881-induced AR overexpression in LNCaP cells 
and PC3 cells increased levels of cyclin A1 in the nucleus, suggest-
ing that AR could either promote trafﬁ  cking of cyclin A1 from the 
cytoplasm to the nucleus or promote its stabilization in the 
nucleus. The nuclear localization of cyclin A1 may be linked to its 
binding, in concert with AR, to the promoter region of VEGF and 
MMP2. 
  Our study has several limitations. One is the lack of an appro-
priate in vivo model to study the cooperative effects of cyclin A1 
and AR on tumor invasion and metastasis. We used PC3 cells to 
initiate the invasive tumors in mice. However, PC3 cells do not 
have functional AR. LNCaP cells contain a functional AR, but 
      Figure 8    .       Cyclin A1 regulates androgen recep-
tor (AR) activity.   A  ) LNCaP cells were trans-
fected with prostate-speciﬁ  c  antigen  (PSA) 
promoter reporter constructs plus either con-
trol vector (C) or cyclin A1  –  expressing vector 
(A1) or AR-expressing vector (AR) or cyclin A1 
and AR vectors (A1/AR) followed by treatment 
with 0.1 nM R1881. Results in A are presented 
as mean luciferase activity of three experi-
ments with 95% conﬁ  dence intervals. The   P   
value is indicated.   B  ) Expression of PSA was 
examined in cells transfected with control 
vectors or cyclin A1- and AR-expressing vec-
tors by immunoblot analysis.       jnci.oxfordjournals.org    JNCI | Articles 1035
when they are subcutaneously injected into mice, the resultant 
tumors are unable to invade to the secondary tissues. Why cyclin 
A1  –  overexpressing tumors are smaller but more invasive compared 
with control tumors is unknown and an appropriate model to sepa-
rate tumor growth from tumor metastasis is needed. In some 
experiments we were limited by the number mice used. For exam-
ple, our results that cyclin A1 overexpression led to increased 
metastasis to lung and liver in an orthotopic tumor mouse model 
did not achieve statistical signiﬁ  cance. Finally, the mechanisms by 
which cyclin A1 is stabilized in the nucleus by AR-mediated path-
ways remain to be elucidated. 
  In conclusion, understanding the mechanisms underlying the 
invasion and metastasis of prostate cancer cells may be essential 
to developing effective therapeutics for the hormone-refractory 
form of the disease. We have shown that overexpression of 
cyclin A1 increased migration and invasiveness of prostate can-
cer in vitro and promoted metastasis. The importance of cyclin 
A1 in tumor cell invasion and metastasis is suggested by its high 
level of nuclear expression in aggressive prostate cancer and its 
ability to mediate the activities of MMPs and VEGF in cultured 
cells.       
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